Sarah is passionate about launching exciting innovations in digital Immunoassay development. In 2012 she was part of a team that put together the commercial strategy for launching the first digital Immunoassay technology into Europe.
In 2015 she joined the Merck Life Science Team, and in 2017 she became part of Merck IPS Leadership Team. Sarah currently works with the global organisation putting together the European commercial strategy and launching of new applications for Merck's newly launched SMCxPRO Immunoassay system. During this time, Sarah has set up successful collaborations with research institutions that have hit the national press. She loves collaborating with scientists who bring untouched SMC applications to life; for instance, quantifying the mutant Huntington protein for the first time and discovering a novel marker to identify heart attacks 6 time faster than current methods.
Sarah has 20 years of commercial experience within the Life Science, and before this, she held a scientific role at Quintiles. She studied Industrial pharmacology at Edinburgh University and graduated from Napier University with an honours degree in Biomedical sciences.